Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
General Internal Medicine
•
Myeloproliferative Neoplasms
•
Hematology
How do you manage and/or prevent ruxolitinib withdrawal syndrome?
Answer from: Medical Oncologist at Community Practice
Generally, tapering over a week or two is the best way to prevent it. If immediate discontinuation is needed, can consider using steroids.
Sign in or Register to read more
14673
Related Questions
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
What experience have you had with familial clustering of polycythemia vera?
How do you decide between using ropeginterferon alfa-2b and peginterferon alfa-2a in MPN?
In which patients with essential thrombocythemia would you use ropeginterferon alfa-2b?
Would you change therapy for a CML patient in hematologic remission on imatinib found with positive qualitative BCR-ABL1 for the p230 protein?
Under which circumstances would you prefer ropeginterferon over hydroxyurea for patients with Polycythemia Vera?
How would you approach post-operative VTE prophylaxis for renal transplant in patients with a prior history of provoked VTE?
For patients with essential thrombocythemia already on prophylactic dose DOACs, do you defer starting aspirin?
For patients with intermediate or lower risk essential thrombocythemia with plt >1000 but no symptoms, do you favor aspirin only therapy or aspirin and cytoreduction?